Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
WINTER SPRINGS, Fla., Jan. 28, 2016 -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that its Board of Directors has approved a stock repurchase program, authorizing the repurchase of up to $10 million of the Company’s common stock through January 28, 2017.
The Company intends to use cash on hand, investments and cash generated from operations to fund the share repurchase program. As of December 31, 2015, the Company had cash, cash equivalents and investments of approximately $27 million.
The timing and amount of the repurchases will be subject to applicable legal requirements including federal and state securities laws. Purchases will be made in open market transactions effected through a broker-dealer at prevailing market prices, in block trades, or in privately negotiated transactions. Any repurchased shares will be available for general corporate purposes.
About IRADIMED CORPORATION
IRADIMED CORPORATION is the only known provider of non-magnetic intravenous (“IV”) infusion pump systems that are specifically designed to be safe for use during magnetic resonance imaging (“MRI”) procedures. We were the first to develop an infusion delivery system that neutralizes the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency (“RF”) interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our MRidium MRI compatible IV infusion pump system has been designed with a patented non-magnetic ultrasonic motor, uniquely-designed non-ferrous parts and other special features in order to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically-ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated in order to remain immobile during an MRI scan.
Media Contact: Chris Scott Chief Financial Officer IRADIMED CORPORATION (407) 677-8022 [email protected]
